GlassScriptPhysician profile
Barry S Katz
NPI 1942266507
$7,903.15
in general payments reported to CMS, 2019-2025
48 companies · $2,463 in 2025
The $2,463 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,367 · 2020: $218 · 2022: $193 · 2023: $1,209 · 2024: $2,454 · 2025: $2,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,125.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $725.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $708.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $672.58 | 2022-2025 | |
| Amgen INC. | $652.46 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $594.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $548.76 | 2019-2025 | |
| Exact Sciences Corporation | $529.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| W. L. Gore & Associates, INC. | $420.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.35 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $212.39 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.91 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Esperion Therapeutics, INC. | $180.08 | 2022-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $177.74 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $165.59 | 2024-2025 | Voquezna |
| Dexcom, INC. | $148.35 | 2023-2025 | Dexcom G6 Transmitter |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.